- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05329155
Early Administration of Heparin at FMC for PPCI of STEMI Patients (HELP-PPCI)
Effectiveness and Safety of Early Administration of Heparin at First Medical Contact for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: a Multicenter, Prospective, Randomized, Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will recruit 944 STEMI patients undergoing primary PCI with the symptom onset within 12 hours in 36 hospitals in Hubei Province, China. The patients will be 1:1 randomly assigned to the intervention group (IG) and control group (CG). Patients in IG will be intravenously administrated with sodium heparin (100U/Kg) at first medical contact, while patients in CG will be administrated with sodium heparin (100U/Kg) through catheter sheath in the CathLab.
Inclusion Criteria:
STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI. Exclusion Criteria:Active bleeding; Life expectancy less than 1 year; History of heparin-induced thrombocytopenia; Mechanical complication of MI (VSR, acute MR); History of CABG; On Coagulation drugs; CPR before randomization; Pregnant or lactating woman;Refused to sign the Informed Consent Form.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Liwei Chen
- Phone Number: 86346 (86)027-88041911
- Email: renminkjc@163.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Renmin Hospital of Wuhan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI
Exclusion Criteria:
- Active bleeding; Life expectancy less than 1 year; History of heparin-induced thrombocytopenia; Mechanical complication of MI (VSR, acute MR); History of CABG; On Coagulation drugs; CPR before randomization; Pregnant or lactating woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Administration of Heparin in ER
Administration of Heparin (100U/Kg body weight) with loading dose of DAPT (Aspirin 300mg and Ticagrelor 180mg) at first medical contact for STEMI patients intended to perform PPCI.
|
Heparin Sodium Injection (100U/Kg body weight)
|
Active Comparator: Administration of Heparin in Cathlab
Administration of Heparin (100U/Kg body weight) in Cathlab after insertion of artery sheath catheter.
|
Heparin Sodium Injection (100U/Kg body weight)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The TIMI 3 flow of the infarct related artery before PCI
Time Frame: Coronary angiography, before PCI,anticipated within 2 hours after randomization
|
The TIMI 3 flow of the infarct related artery at diagnostic angiography before PCI
|
Coronary angiography, before PCI,anticipated within 2 hours after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete epicardial and myocardial reperfusion after PPCI
Time Frame: within 90min after PPCI
|
Thrombolysis in myocardial infarction (TIMI) flow grade (TFG) 3 for epicardial reperfusion and TIMI myocardial perfusion (TMPG) grade 3 for myocardial reperfusion and complete (≥70%) ST-segment resolution of the initial sum of ST-segment elevation (STR) 60 minutes after PCI.
|
within 90min after PPCI
|
Major adverse cardiovascular or cerebrovascular event
Time Frame: 30 day and 1 year after randomization
|
death, cardiac death, admission for heart failure, myocardial infarction, stent thrombosis, unplanned revascularization, and stroke
|
30 day and 1 year after randomization
|
Major bleeding
Time Frame: 30 day after randomization
|
BARC ≥2
|
30 day after randomization
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jing Chen, PhD, Renmin Hospital of Wuhan University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Heparin
- Calcium heparin
Other Study ID Numbers
- WDRY2022-K089
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on STEMI
-
Clinical Operations WCN B.V.SanofiEnrolling by invitationAtherosclerotic Cardiovascular Disease | STEMI | Non STEMINetherlands
-
Kingston UniversityUniversity of Leeds; Swansea University; London Ambulance Service; West Midlands... and other collaboratorsCompletedAcute Coronary Syndrome | STEMI | Non STEMIUnited Kingdom
-
Karolinska InstitutetEnrolling by invitation
-
Beijing Friendship HospitalActive, not recruiting
-
University of OradeaCompleted
-
Prolocor, IncRecruitingSTEMI | NSTEMIUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedPrimary PCI - STEMIFrance
-
VesalioRecruitingSegment Elevation Myocardial Infarction (STEMI)Switzerland
-
University of PisaCompleted
-
AstraZenecaCompletedMyocardial Infarction | Segment Elevation Myocardial Infarction (STEMI)Australia, France, Italy, Spain, United Kingdom, Sweden, Germany, Hungary, Denmark, Austria, Canada, Netherlands, Algeria
Clinical Trials on Heparin Sodium Injection
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Hospital General "Dr. Miguel Silva" de MoreliaUniversidad Nacional Autonoma de Mexico; NAUSLIFE HEMODIALYSIS CLINICSUnknownEnd Stage Renal Disease | Hemodialysis Access Failure | Vascular Access Complication | Catheter Complications | Hemodialysis Catheter InfectionMexico
-
Xuanwu Hospital, BeijingCompletedCerebral Angiography | HeparinizationChina
-
Beni-Suef UniversityCompletedSevere Acute Respiratory Syndrome | Acute Respiratory Distress Syndrome
-
Azidus BrasilUnknown
-
Azidus BrasilCompleted
-
Azidus BrasilUnknownCardiac SurgeryBrazil